NASDAQ:SNTS - Santarus Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
Previous CloseN/A
Today's RangeN/A
52-Week RangeN/A
VolumeN/A
Average VolumeN/A
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Santarus logoSantarus, Inc. (Santarus) is a specialty biopharmaceutical company focused on acquiring, developing and commercializing products that address the needs of patients treated by physician specialists. As of December 31, 2012, the Company's marketed and approved products included Uceris (budesonide), Zegerid (omeprazole/sodium bicarbonate), Glumetza (metformin hydrochloride extended release tablets), Cycloset (bromocriptine mesylate) tablets and Fenoglide (fenofibrate) tablets. As of December 31, 2012, the Company's investigational drugs included Ruconest (recombinant human C1 esterase inhibitor), Rifamycin SV MMX, and SAN-300 (anti-VLA-1 antibody). In January 2014, Salix Pharmaceuticals, Ltd. acquired Santarus, Inc.

Receive SNTS News and Ratings via Email

Sign-up to receive the latest news and ratings for SNTS and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry N/A
Sub-IndustryPharmaceuticals
SectorN/A
SymbolNASDAQ:SNTS
CUSIP80281730
Phone+1-858-3145700

Debt

Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A

Profitability

EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net MarginsN/A
Return on EquityN/A
Return on AssetsN/A

Miscellaneous

EmployeesN/A
Outstanding SharesN/A
Market Cap$0.00

The Truth About Cryptocurrencies

Santarus (NASDAQ:SNTS) Frequently Asked Questions

What is Santarus' stock symbol?

Santarus trades on the NASDAQ under the ticker symbol "SNTS."

What is the consensus analysts' recommendation for Santarus?

0 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Santarus in the last year. There are currently for the stock, resulting in a consensus recommendation of "N/A."

Has Santarus been receiving favorable news coverage?

News stories about SNTS stock have been trending somewhat positive recently, Accern Sentiment reports. The research firm identifies negative and positive news coverage by analyzing more than 20 million news and blog sources in real-time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Santarus earned a news sentiment score of 0.04 on Accern's scale. They also gave news stories about the biopharmaceutical company an impact score of 43.35 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the company's share price in the immediate future.

How do I buy shares of Santarus?

Shares of SNTS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How can I contact Santarus?

Santarus' mailing address is 3611 Valley Centre Dr Ste 400, SAN DIEGO, CA 92130-3331, United States. The biopharmaceutical company can be reached via phone at +1-858-3145700.


MarketBeat Community Rating for Santarus (NASDAQ SNTS)

Community Ranking:  2.8 out of 5 (star star)
Outperform Votes:  89 (Vote Outperform)
Underperform Votes:  71 (Vote Underperform)
Total Votes:  160
MarketBeat's community ratings are surveys of what our community members think about Santarus and other stocks. Vote "Outperform" if you believe SNTS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe SNTS will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 7/16/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.